Novo Nordisk announced the headline results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The 52-week, open label trial investigated the efficacy and safety of 14 mg oral semaglutide compared with 25…
Generic Version Of Vagifem In U.S. Impacts Novo Nordisk Biopharma Sales
Reported sales were broadly unchanged at $16.9 billion (2 percent growth in local currencies). Sales within biopharmaceuticals declined by 18 percent to $2.9 billion (16 percent in local currencies), reflecting the impact in the U.S. from the introduction of a generic version of the hormone replacement therapy product Vagifem and a rebate adjustment for growth hormone…
Novo Nordisk Awards $40M Automation Contract For New U.S. Manufacturing Facility
Novo Nordisk selects Emerson to help bring medication to market more quickly to address growing diabetes epidemic. Global healthcare company Novo Nordisk has awarded Emerson a $40 million automation systems and services contract for a new U.S.-based drug manufacturing facility to help battle the global diabetes epidemic. The largest project in its history, Novo Nordisk’s new…